+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Castleman Disease Treatment Market by Treatment Type, Distribution Channel, End User, Line of Therapy - Global Forecast to 2030- Product Image
Castleman Disease Treatment Market by Treatment Type, Distribution Channel, End User, Line of Therapy - Global Forecast to 2030- Product Image
Sale

Castleman Disease Treatment Market by Treatment Type, Distribution Channel, End User, Line of Therapy - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5336683
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Castleman Disease Treatment Market grew from USD 334.15 million in 2024 to USD 380.66 million in 2025. It is expected to continue growing at a CAGR of 13.67%, reaching USD 720.87 million by 2030.

Unveiling the Promise of Evolving Castleman Disease Therapies

Castleman disease represents a complex spectrum of lymphoproliferative disorders characterized by atypical lymph node growth and systemic inflammatory responses. Despite its rarity, the disease imposes serious clinical challenges, spanning from unicentric presentations manageable by localized interventions to multicentric variants requiring systemic therapies. Variability in disease severity and patient comorbidities demands a nuanced understanding of evolving treatment modalities and patient pathways.

Recent advances have reshaped the therapeutic paradigm for Castleman disease, introducing targeted monoclonal antibodies alongside established chemotherapy regimens and corticosteroid protocols. Agents such as siltuximab and tocilizumab have gained prominence, while dexamethasone and prednisone remain foundational cornerstones. Combination therapy approaches are emerging to enhance response rates in refractory cases, whereas monotherapy options continue to serve patients with milder presentations or contraindications to multi-agent regimens.

This executive overview distills the latest industry developments, regulatory influences, and competitive dynamics that will shape strategic decision-making. By synthesizing key findings across treatment types, distribution channels, end users, and geographic markets, this summary equips stakeholders with actionable intelligence to optimize clinical outcomes, align with payer expectations, and anticipate market shifts.

Shifting Paradigms Redefine the Castleman Disease Landscape

The Castleman disease treatment environment is undergoing transformative shifts driven by scientific breakthroughs, regulatory momentum, and patient advocacy. Approval of targeted interleukin-6 inhibitors has set a precedent for precision interventions, while advancements in diagnostic imaging and molecular profiling have enriched disease characterization and individualized care pathways. These developments are prompting a move away from broad-spectrum cytotoxic regimens toward therapies tailored to specific pathophysiological mechanisms.

Concurrently, mounting emphasis on health economics is reshaping formulary decisions and reimbursement frameworks. Stakeholders increasingly demand real-world evidence on efficacy, safety, and cost-effectiveness, driving manufacturers to invest in robust post-marketing studies and patient registries. Digital health solutions are enhancing patient engagement and remote monitoring, enabling proactive management of treatment adherence and adverse event reporting.

As clinical practice guidelines evolve to incorporate novel biologics and optimized dosing schemas, care delivery models are adapting to support multidisciplinary collaboration among hematologists, immunologists, and specialty pharmacists. These paradigm shifts underscore the need for flexible strategies that balance rapid innovation adoption with sustainable access and affordability.

Navigating the Ripple Effects of US Tariffs on Treatment Accessibility

Recent implementation of cumulative tariffs on active pharmaceutical ingredients and finished dosage forms has introduced new complexities into the Castleman disease treatment supply chain. Increased import duties have elevated production costs for intravenous biologics and sterile injectables, prompting manufacturers to reassess sourcing strategies and manufacturing footprints. This cost pressure is especially acute for monoclonal antibodies that rely on high-purity reagents and stringent cold chain logistics.

Providers face rising expenses that translate into higher acquisition costs at hospital and retail pharmacies, potentially straining reimbursement budgets and impacting patient affordability. To mitigate margin erosion, distributors and payers are exploring value-based contracting models that link pricing to treatment outcomes. Some pharmaceutical companies are launching patient assistance initiatives to preserve access, while others are localizing component production to circumvent tariff barriers.

In this environment, strategic alliances with contract manufacturers and logistics partners have become critical to maintaining uninterrupted supply and controlling end-to-end costs. Companies are also evaluating tariff classification optimizations and leveraging free trade agreements to reduce duty burdens. These adaptive measures will be essential to sustaining therapeutic availability and ensuring equitable patient access under the new tariff regime.

Interpreting Patient and Treatment Segments for Targeted Strategies

Deep analysis of treatment modalities reveals that chemotherapy protocols for Castleman disease split between combination and monotherapy approaches, while corticosteroid regimens differentiate into dexamethasone and prednisone options. Meanwhile, targeted immunotherapies with siltuximab and tocilizumab are evaluated as standalone interventions or part of integrated regimens for refractory cases.

Distribution channels range from inpatient pharmacies within hospital settings to outpatient dispensaries, as well as online platforms and retail outlets. The latter category distinguishes between large chain networks and independent community pharmacies, reflecting divergent procurement practices, dispensing volumes, and patient support services.

End users comprise patients receiving care at home, facilitated either by self-administration models or visiting nurse programs, alongside those treated in acute hospital environments and specialty clinics. Each setting presents unique reimbursement mechanisms, training requirements, and monitoring protocols that influence therapy uptake and adherence.

Line-of-therapy segmentation further refines market insights into first-line regimens-whether monotherapy or combination therapy-and subsequent second-line or later-line interventions reserved for patients with suboptimal initial responses. This layered segmentation framework illuminates distinct patient cohorts, treatment pathways, and revenue dynamics critical for targeted strategy development.

Regional Dynamics Shape Growth Across Key Geographies

In the Americas region, established healthcare infrastructures and well-defined reimbursement landscapes support rapid adoption of innovative Castleman disease therapies. Active patient advocacy and robust clinical trial networks drive awareness, but cost containment imperatives and payer scrutiny demand clear evidence of value and real-world outcomes.

Europe, Middle East & Africa present a mosaic of diverse regulatory frameworks and market access pathways. In Western Europe, centralized approval processes facilitate timely product launches, while pricing negotiations and health technology assessments shape uptake. In emerging markets across the Middle East and Africa, limited specialist capacity and evolving reimbursement systems challenge manufacturers to tailor access programs and stakeholder education efforts.

Asia-Pacific encompasses both mature markets with strong biologics manufacturing capabilities and high-growth territories characterized by rising patient awareness and expanding healthcare spending. In regions with local production incentives and favorable trade policies, cost-sensitive tendering environments co-exist with premium markets that prioritize fastest-to-market availability. Supply chain optimization and strategic partnerships are paramount to navigate regulatory variances and support equitable patient access.

Competitive Forces Driving Innovation in Castleman Disease Care

Leading pharmaceutical innovators are actively shaping the Castleman disease treatment arena through strategic R&D investments, alliance formations, and lifecycle management initiatives. Major players with approved interleukin-6 inhibitors maintain dedicated clinical development programs aimed at broadening label indications and exploring subcutaneous formulations to enhance patient convenience.

Competitors are advancing pipeline assets targeting alternative cytokine pathways, while others invest in biosimilar development to address cost barriers. Collaborative research agreements between industry and academic centers underpin translational studies, focusing on biomarkers that predict therapeutic response and optimize patient selection.

Distribution partners and specialty pharmacies are forging service-level agreements to deliver infusion services and support adherence through patient education platforms and digital monitoring tools. Biotech firms are also leveraging real-world evidence networks to demonstrate long-term safety and cost-effectiveness, thereby strengthening payer negotiations and formulary positioning.

Strategic Imperatives to Thrive in a Transforming Market

Industry leaders should prioritize expanding biologics manufacturing capacity in regions with favorable trade policies to mitigate tariff-induced cost pressures and enhance supply resilience. Establishing joint ventures with contract development and manufacturing organizations will enable flexible scaling and localized production, reducing lead times and duty exposures.

Strategic engagement with payers through value-based contracting models can align pricing with clinical outcomes while addressing affordability concerns. Companies should invest in real-world data collection via patient registries and digital health platforms to substantiate long-term benefits and reinforce formulary positioning.

To reach diverse patient segments effectively, manufacturers ought to tailor distribution strategies that integrate inpatient, outpatient, online, and retail channels, complemented by specialized training for home care providers. Collaborations with advocacy groups and research consortia will facilitate broader disease awareness, accelerate trial recruitment, and support evidence generation.

Robust Research Approach Underpinning Actionable Insights

This analysis rests on a rigorous multi-stage research methodology combining exhaustive secondary research and targeted primary engagements. Initial data gathering leveraged peer-reviewed journals, regulatory filings, company disclosures, and industry white papers to build a foundational understanding of therapeutic landscapes, competitive dynamics, and tariff regulations.

Subsequent primary research involved in-depth interviews with key opinion leaders, treatment center directors, payers, and patient advocacy representatives to validate hypotheses and capture nuanced market sentiments. Quantitative data points from global healthcare databases were triangulated against qualitative insights to ensure consistency and reliability.

An iterative validation process included cross-referencing estimates with expert feedback and reconciling discrepancies through follow-up inquiries. Segmentation analysis, competitive profiling, and thematic synthesis provided the structural backbone for generating actionable insights tailored to diverse stakeholder needs.

Synthesis of Insights and Forward-Looking Perspectives

The synthesis of emerging scientific advances, evolving reimbursement landscapes, and geopolitical influences shapes a dynamic Castleman disease market that demands agile strategies. Segmentation by treatment type, channel, end user, and line of therapy reveals critical patient pathways and revenue pockets that can be leveraged for competitive advantage.

Regional nuances underscore the importance of customizing access initiatives and distribution models to local regulatory and economic contexts. Concurrently, key companies are harnessing innovation in biologics, biosimilars, and digital services to differentiate their offerings and strengthen market positions.

By integrating tactical recommendations-such as localized manufacturing, value-based agreements, and comprehensive real-world evidence programs-industry leaders can align stakeholder interests, sustain therapeutic access, and deliver meaningful outcomes for patients with Castleman disease.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Chemotherapy
      • Combination Therapy
      • Monotherapy
    • Corticosteroids
      • Dexamethasone
      • Prednisone
    • Siltuximab
    • Tocilizumab
  • Distribution Channel
    • Hospital Pharmacies
      • Inpatient Pharmacies
      • Outpatient Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
      • Chain Pharmacies
      • Independent Pharmacies
  • End User
    • Home Care Settings
      • Self Administration
      • Visiting Nurse Services
    • Hospitals
    • Specialty Clinics
  • Line Of Therapy
    • First Line
      • Combination Therapy
      • Monotherapy
    • Later Lines
    • Second Line
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Janssen Biotech, Inc.
  • Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • EUSA Pharma (UK) Limited
  • Swedish Orphan Biovitrum AB
  • Grifols, S.A.
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Bristol-Myers Squibb Company

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Castleman Disease Treatment Market, by Treatment Type
8.1. Introduction
8.2. Chemotherapy
8.2.1. Combination Therapy
8.2.2. Monotherapy
8.3. Corticosteroids
8.3.1. Dexamethasone
8.3.2. Prednisone
8.4. Siltuximab
8.5. Tocilizumab
9. Castleman Disease Treatment Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.2.1. Inpatient Pharmacies
9.2.2. Outpatient Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
9.4.1. Chain Pharmacies
9.4.2. Independent Pharmacies
10. Castleman Disease Treatment Market, by End User
10.1. Introduction
10.2. Home Care Settings
10.2.1. Self Administration
10.2.2. Visiting Nurse Services
10.3. Hospitals
10.4. Specialty Clinics
11. Castleman Disease Treatment Market, by Line of Therapy
11.1. Introduction
11.2. First Line
11.2.1. Combination Therapy
11.2.2. Monotherapy
11.3. Later Lines
11.4. Second Line
12. Americas Castleman Disease Treatment Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Castleman Disease Treatment Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Castleman Disease Treatment Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Janssen Biotech, Inc.
15.3.2. Hoffmann-La Roche Ltd
15.3.3. Pfizer Inc.
15.3.4. EUSA Pharma (UK) Limited
15.3.5. Swedish Orphan Biovitrum AB
15.3.6. Grifols, S.A.
15.3.7. AbbVie Inc.
15.3.8. Takeda Pharmaceutical Company Limited
15.3.9. Novartis AG
15.3.10. Bristol-Myers Squibb Company
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. CASTLEMAN DISEASE TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. CASTLEMAN DISEASE TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. CASTLEMAN DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CASTLEMAN DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CASTLEMAN DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CASTLEMAN DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SILTUXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TOCILIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY VISITING NURSE SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LATER LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 63. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 64. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 65. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 66. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 68. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 69. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 71. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 72. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 73. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 75. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 76. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 78. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 79. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 82. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 124. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 125. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 126. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 127. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 129. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 130. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 132. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 133. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 134. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 135. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 136. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 137. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 139. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 140. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 142. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 143. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 154. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 155. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 156. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 157. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 159. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 160. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 162. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 163. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 164. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 165. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 166. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 167. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 169. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 170. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 172. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 173. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 174. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 175. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 176. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 184. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 185. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 186. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 194. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 195. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 196. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 204. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 205. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 206. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 207. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 209. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 210. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 212. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 213. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 214. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 215. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 216. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 217. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 224. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 225. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 226. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 227. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 229. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 230. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 232. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 233. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 234. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 235. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 236. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 237. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 239. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 240. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 242. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 243. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 244. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 245. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 246. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 254. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 255. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 256. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 257. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 264. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 265. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 266. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 267. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 269. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 270. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 272. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 273. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 274. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 275. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 276. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 277. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 279. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 280. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 282. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 283. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 284. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 285. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 286. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 287. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 288. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 289. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 294. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 295. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 296. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 297. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 298. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 299. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 300. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 302. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 303. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 304. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 305. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 306. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 307. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 309. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 310. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Castleman Disease Treatment market report include:
  • Janssen Biotech, Inc.
  • Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • EUSA Pharma (UK) Limited
  • Swedish Orphan Biovitrum AB
  • Grifols, S.A.
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Bristol-Myers Squibb Company

Table Information

Report AttributeDetails
No. of Pages190
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 380.66 Million
Forecasted Market Value ( USD ) by 2030 $ 720.87 Million
Compound Annual Growth Rate13.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

idiopathic Multicentric Castleman's Disease (iMCD) - Pipeline Insight, 2025 - Product Image

idiopathic Multicentric Castleman's Disease (iMCD) - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Castleman Disease - Pipeline Insight, 2025 - Product Image

Castleman Disease - Pipeline Insight, 2025

  • Clinical Trials
  • 40 Pages
  • Global
From
Non-Hodgkin Lymphoma Treatment Market by Treatment Type, Distribution Channel, Therapy Class, Line of Therapy, Histologic Subtype, End User, Disease Stage, Patient Age Group - Global Forecast to 2030 - Product Image

Non-Hodgkin Lymphoma Treatment Market by Treatment Type, Distribution Channel, Therapy Class, Line of Therapy, Histologic Subtype, End User, Disease Stage, Patient Age Group - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Krabbe Disease Treatment Market by Therapy Type, Administration Route, Treatment Setting, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030 - Product Image

Krabbe Disease Treatment Market by Therapy Type, Administration Route, Treatment Setting, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030

  • Report
  • 187 Pages
  • Global
From
Dopamine Agonist Market Size, Share & Trends Analysis Report by Drug (Non-Ergot Dopamine Agonists, Ergot Alkaloids), Route of Administration (Oral, Injectable), Application, Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Image

Dopamine Agonist Market Size, Share & Trends Analysis Report by Drug (Non-Ergot Dopamine Agonists, Ergot Alkaloids), Route of Administration (Oral, Injectable), Application, Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • 153 Pages
  • Global
From

About the Castleman Disease Drugs Market

Castleman Disease (CD) is a rare lymphoproliferative disorder that affects the lymph nodes and other organs. It is classified as a subtype of lymphoma, and is characterized by an overgrowth of lymphoid cells. Treatment for CD typically involves chemotherapy, radiation therapy, and/or immunosuppressive drugs. The Castleman Disease Drugs market is a subset of the larger Lymphoma Drugs market. It is composed of drugs used to treat CD, such as monoclonal antibodies, interferons, and corticosteroids. These drugs are used to reduce the size of lymph nodes, reduce inflammation, and suppress the immune system. Some companies in the Castleman Disease Drugs market include AbbVie, Bristol-Myers Squibb, Celgene, Gilead Sciences, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.